Genetic testing for hereditary breast cancer in Poland: 1998–2022

Hereditary Cancer in Clinical Practice

Comment

Steven A Narod¹  Anna Jakubowska²  Jacek Gronwald²  Jan Lubinski²  Tadeusz Debniak²  Tomasz Huzarski²  Marcin Lener²  Cezary Cybulski² 

[1] Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada;Womens College Research Institute, Toronto, ON, Canada;International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland;

关键词: BRCA1;    BRCA2;    Breast Cancer;    Genetic testing;   

DOI  :  10.1186/s13053-023-00252-6

 received in 2023-03-09, accepted in 2023-05-24,  发布年份 2023

来源: Springer

【 摘 要 】

BRCA1 and BRCA2 mutations contribute to both breast cancer and ovarian cancer worldwide. In Poland approximately 4% of patients with breast cancers and 10% of patients with ovarian cancer carry a mutation in BRCA1. The majority of mutations consist of three founder mutations. A rapid inexpensive test for these three mutations can be used to screen all Polish adults at a reasonable cost. In the region of Pomerania of North-western Poland nearly half a million tests have been performed, in large part through engaging family doctors and providing ready access to testing through the Pomeranian Medical University. The following commentary provides a history of genetic testing for cancer in Pomerania and the current approach to facilitating access to genetic testing at the Cancer Family Clinic for all adults living in the region.

【 授权许可】

CC BY   
© The Author(s) 2023